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and, subsequent to tumor shrinkage, underwent resec-
tion with subtotal hepatectomy.
Case report
A 56-year-old woman was initially seen at another insti-
tution for a 2-month history of nausea and right upper
quadrant pain. An abdominal computed tomographic
scan revealed a large hepatic mass involving the left
liver and the right anterior sector. The pathologic inter-
pretation of a fine-needle biopsy of the liver tumor was
initially adenocarcinoma. Because the patient had un-
dergone a modified radical mastectomy for invasive
ductal carcinoma (T1N1) of the left breast 5 years prior
to this presentation, she was presumed to have recur-
rent breast cancer with hepatic metastases. Systemic
chemotherapy with docetaxel (75mg/m2 i.v. every 3
weeks × four courses) and capecitabine (500mg p.o.
twice daily for approximately 82 days) was adminis-
tered, with no reduction in the size of the hepatic
mass. The patient was then referred to The
University of Texas M. D. Anderson Cancer Center for
consultation.
On evaluation at M. D. Anderson Cancer Center,
repeat computed tomographic imaging revealed a large
mass centered in the medial left liver with extension
into the anterior sector of the right liver (Fig. 1). All
three suprahepatic veins were involved by tumor. Be-
cause of the extent of the vascular involvement, surgical
resection was not deemed possible. Imaging character-
istics suggested the possibility of HCC, rather than
breast cancer, and the serum alpha-fetoprotein level
supported this suspicion (3900ng/ml). Direct compari-
son of the liver biopsy to the original breast carcinoma
revealed that the cytology and histology were convinc-
ingly different and were diagnostic of HCC in the liver
tumor. Immunohistochemical stains on the liver biopsy
(carbohydrate antigen [CA]225, cytokeratin [CK7,
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Introduction
Surgical resection remains the only potentially curative
treatment for patients with hepatocellular carcinoma
(HCC). Because most patients have unresectable dis-
ease at the time of diagnosis, their prognosis is poor.
Although randomized trials have failed to show that
chemotherapeutic agents alone improve survival in pa-
tients with HCC, chemotherapy in the neoadjuvant set-
ting combined with more aggressive surgical techniques
may enable resection with curative intent in selected
cases.1 In 1987, Makuuchi and colleagues2 proposed a
resection technique — later termed subtotal hepatec-
tomy — in which only the inferior right hepatic vein
(IRHV) was preserved as outflow for the right posterior
liver when all three main hepatic veins were resected. In
this report, we describe a case in which a patient with
unresectable HCC received neoadjuvant chemotherapy
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AE1/AE3], carcinoembryonic antigen [CEA]) were
negative (metastasis from breast cancer would be ex-
pected to be CK7 and AE1/AE3+).
Transarterial chemoembolization (TACE) with
doxorubicin (30mg i.a.) and mitomycin-C (15mg i.a.)
led to a fall in alpha fetoprotein and a radiographic
response, but the tumors remained unresectable due to
extensive persistent involvement of the left and middle
hepatic veins, and persistent tumor in contact with the
proximal right hepatic vein (Fig. 2). Due to concerns
over the tissue diagnosis, the patient’s primary oncolo-
gist pursued further chemotherapies directed at a can-
cer of unknown primary and/or breast cancer. These
included single-agent paclitaxel (100mg/m2 i.v., three
weekly doses over 4 weeks), and then combination che-
motherapy (gemcitabine, 800mg/m2 i.v.; 5-fluorouracil,
500mg/m2 i.v.; and leucovorin, 500mg i.v., for four
weekly doses over 5 weeks). A modest reduction in
tumor size was noted, and consideration was given to
resection if further response could be achieved. After
further consultation at M. D. Anderson Cancer Center
and with focus on the diagnosis of HCC, treatment with
a modified PIAF regimen was initiated (cisplatin, 20mg/
m2 i.v. days 1–4; mitoxantrone, 12mg/m2 i.v. day 1;
5-fluorouracil, 400mg/m2 i.v. days 1–4; and alpha-
interferon, 5 million units/m2 s.c. days 1–4; prior doxoru-
bicin exposure led to substitution with mitoxantrone).
The first course was administered with a 15% dose re-
duction and all subsequent courses were administered
at full doses. After four (monthly) cycles of modified
PIAF treatment, the serum alpha-fetoprotein level de-
creased to 6ng/ml, and the tumor mass was markedly
smaller. In addition, the IRHV, which had been visible
but diminutive on prior imaging, appeared more promi-
nent after tumor shrinkage (Fig. 3). An extended left
hepatectomy with resection of all three main hepatic
veins, preserving the IRHV, was judged to be possible.
At the time of laparotomy, tumor involvement of
Couinaud segments I through V, VIII, and the superior
portion of VII was found, with sparing of the right pos-
terior portal structures, segment VI, and the inferior
portion of segment VII. Sonography confirmed the CT
findings, including an enlarged venous branch anterior
to the right posterior portal branch (Fig. 3a); large tribu-
Fig. 1a,b. Enhanced computed tomographic (CT) scan of the abdomen before treatment revealed an ill-defined tumor (black
arrows) involving the left liver, all three hepatic veins, and extending to segments VIII, VII, and I
Fig. 2. Enhanced CT scan of the abdomen after chemo-
therapy and transarterial chemoembolization (TACE), at the
same level as that before treatment, showed a dramatic im-
provement, but the persistent, treated tumor involved the
right suprahepatic vein (black arrows). The remaining tumor
in the left liver had obliterated the left and middle hepatic
veins (not seen in this image). Focal areas of ischemia were
seen in the right lobe (arrowheads)
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taries draining segments VI and VII (Fig. 3b–d) had
joined to form an enlarged vein entering the inferior
vena cava behind the right portal pedicle, about 5cm
caudal to the main RHV (Fig. 4). Thus, the hepatic
venous drainage of the posterior right sector defined on
CT imaging and intraoperative sonography was consis-
tent with the description of the IRHV from Makuuchi
et al.3 and discussed by others.4–6 The tumor in segment
VII made resection of the right hepatic vein with the
superior portion of segment VII mandatory to achieve a
complete tumor resection. The IRHV was of similar
caliber to the main RHV (Fig. 4). An extended left
hepatectomy with en-bloc caudate lobectomy and re-
section of all three main hepatic veins was performed
(i.e., a subtotal hepatectomy). The residual liver con-
sisted of segment VI and the inferior portion of segment
VII drained through the enlarged IRHV. Pathologic
analysis of the resected specimen revealed necrotic tis-
sue without residual viable tumor and no evidence of
tumor at the parenchymal resection margin.
The patient’s postoperative course was unremark-
able, and 40 months after surgery, she is alive with no
evidence of disease.
Discussion
Important advances in the treatment of HCC are largely
the result of the expanded use of systemic and liver-
directed therapies, including chemotherapy, TACE,
and advanced surgical techniques. When used in a
multimodality approach, these therapies offer the po-
tential for improved outcomes in patients with HCC.
In the case of this patient, an initially unresectable
Fig. 3. a The anterior tributary of the large inferior hepatic
vein draining directly into the inferior vena cava (white
arrows) is shown. Focal areas of ischemia were seen in the
right lobe (black arrowheads). Treated tumor in segment VIII
(black arrows). b–d Additional large tributaries of the inferior
hepatic vein surrounding the posterior right portal vein are
shown (white arrows), which converge to drain into the vein
demonstrated in a. This inferior vein ultimately drains into the
inferior vena cava (IVC) posterior to the right portal pedicle,
approximately 5cm caudal to the main right suprahepatic vein
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tumor was rendered resectable after the use of newer-
generation neoadjuvant chemotherapy.
HCC is largely resistant to chemotherapy. Treatment
using single agents is associated with a tumor response
rate of 20% and a median duration of patient survival of
about 4 months. Combination chemotherapy has been
used with higher response rates, but multiple random-
ized trials have found no difference in overall survival.
Using the PIAF regimen in patients with preserved liver
function (and minimal or no cirrhosis), Lau and col-
leagues1 found 18% major tumor response rate (more
than 50% reduction in tumor size). Furthermore, 10%
percent of the entire cohort, who presented with tumors
that were considered unresectable, underwent subse-
quent complete resection after chemotherapy; 53% of
the resected patients were alive 3 years after hepatic
resection.1 The PIAF treatment regimen may allow a
selected group of patients with HCC confined to the liver
to become eligible for aggressive surgical techniques.1,7
Newer, more extensive techniques for resection con-
tinue to expand the pool of patients with HCC who are
candidates for potentially curative surgery.2 The limit-
ing factor remains the volume and function of the future
Fig. 4. Intraoperative photograph depicting inferior right he-
patic vein (arrow) clearly seen from the patient’s left side after
the trunk of the middle and left hepatic veins has been
divided, and the left liver and caudate lobe (CL) have been
elevated from the inferior vena cava (IVC). The right hepatic
vein (arrowhead) is encircled with a tape before resection,
leaving only the inferior right hepatic vein, segment VI, and a
portion of segment VII
liver remnant, which requires sufficient arterial and por-
tal inflow and hepatic venous outflow. Resection and
reconstruction of hepatic veins has been used to maxi-
mize remaining liver volume in patients with cirrhosis
and to obtain clear margins in tumors involving the
hepatic veins. Greatly enlarged accessory veins draining
the posterior inferior right liver, termed “middle and
inferior right hepatic veins,” are identified in 10% to
24% of patients who undergo hepatic imaging.3 The
presence of an enlarged IRHV, as in our patient, obvi-
ates the need to reconstruct the major hepatic veins.
Previous authors have described the use of hepatic vein
embolization of a main hepatic vein to enlarge the
IRHV.8 Our patient underwent TACE, which may
have promoted maturation of the IRHV in the interim
between TACE and surgery, particularly because her
middle and left hepatic veins were completely occluded
and the main right hepatic vein was involved by tumor.
Unlike previous reports,9 to our knowledge, this is the
first reported case of subtotal hepatectomy after se-
quential TACE and neoadjuvant chemotherapy. In
conclusion, the combination of innovative neoadjuvant
chemotherapy and well-planned surgical approaches
may enable a small number of patients with previously
unresectable HCC to become candidates for complete
surgical resection, particularly as newer, more effective
neoadjuvant therapy regimens are developed.
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